These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9835534)

  • 1. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.
    Mimoz O; Jacolot A; Leotard S; Hidri N; Samii K; Nordmann P; Petitjean O
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3304-8. PubMed ID: 9835534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
    Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
    Mimoz O; Leotard S; Jacolot A; Padoin C; Louchahi K; Petitjean O; Nordmann P
    Antimicrob Agents Chemother; 2000 Apr; 44(4):885-90. PubMed ID: 10722486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo.
    Mimoz O; Jacolot A; Padoin C; Caillon J; Louchahi K; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1997 Mar; 39(3):363-9. PubMed ID: 9096186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae.
    Chan WC; Li RC; Ling JM; Cheng AF; Schentag JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):55-60. PubMed ID: 10381101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F; Quentin C
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Szabó D; Máthé A; Filetóth Z; Anderlik P; Rókusz L; Rozgonyi F
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1287-91. PubMed ID: 11257049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
    Bantar C; Di Chiara M; Nicola F; Relloso S; Smayevsky J
    Diagn Microbiol Infect Dis; 2000 May; 37(1):41-4. PubMed ID: 10794939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.
    Pechère JC; Vladoianu IR
    J Antimicrob Chemother; 1992 May; 29(5):563-73. PubMed ID: 1624394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Jones RN; Salazar JC; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHV-12 extended spectrum beta-lactamase associated with high-level ceftazidime resistance in Enterobacter cloacae isolated from Thailand.
    Tansawai U; Boonkerd N; Polwichai P; Dejsirilert S; Niumsup PR
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):148-54. PubMed ID: 19323047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae.
    Jacolot A; Judel C; Chaumais MC; Louchahi K; Nicolas P; Marchand S; Petitjean O; Mimoz O
    Chemotherapy; 2012; 58(2):129-33. PubMed ID: 22572147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.
    Jones RN; Marshall SA
    Diagn Microbiol Infect Dis; 1994 May; 19(1):33-8. PubMed ID: 7956010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.